UBS raised the firm’s price target on Xylem (XYL) to $133 from $132 and keeps a Neutral rating on the shares. This is expected to be a transitory year for Xylem, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XYL: